Migraine and patent foramen ovale: A residual coincidence or a pathophysiological intrigue?

Cerebrovascular Diseases

Volumn 22, Issue 2-3, 2006, Pages 91-100

  Piechowski Jozwiak, B ^a,b   Devuyst, G ^a   Bogousslavsky, J ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Migraine; Patent foramen ovale; Right to left shunting

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

AGE DISTRIBUTION; ANGINA PECTORIS; BRAIN INFARCTION; BRAIN INFARCTION SIZE; CADASIL; CLINICAL FEATURE; COMORBIDITY; CORONARY ARTERY SPASM; DEPRESSION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; EPILEPSY; FAMILIAL HEMIPLEGIC MIGRAINE; HEADACHE; HEART ATRIUM SEPTUM DEFECT; HUMAN; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; MITRAL VALVE PROLAPSE; MUSCULOSKELETAL DISEASE; PANIC; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SEX DIFFERENCE; STROKE; TRANSIENT ISCHEMIC ATTACK; WHITE MATTER;

CEREBROVASCULAR DISORDERS; EMBOLISM, PARADOXICAL; HEART CATHETERIZATION; HEART SEPTAL DEFECTS, ATRIAL; HUMANS; MIGRAINE DISORDERS;

EID: 33746351336     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093236     Document Type: Review

References (123)

1. Classification and WHO ICD-10NA codes. Cephalalgia 2004;24:16-22.
2. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia 1988;8(suppl 7):1-96.
3. Stewart WF, Simon D, Shechter A, Lipton RB: Population variation in migraine prevalence: a meta-analysis. J Clin Epidemiol 1995;48:269-280.
4. Spierings EL: Pathogenesis of the migraine attack. Clin J Pain 2003;19:255-262.
5. Welch KM: Contemporary concepts of migraine pathogenesis. Neurology 2003;61:S2-S8.
6. Pietrobon D, Striessnig J: Neurobiology of migraine. Nat Rev Neurosci 2003;4:386-398.
7. Peroutka SJ: Migraine: a chronic sympathetic nervous system disorder. Headache 2004;44:53-64.
8. Goadsby PJ, Lipton RB, Ferrari MD: Migraine - current understanding and treatment. N Engl J Med 2002;346:257-270.
9. Liveing E: On Megrim, Sick-Headache, and Some Allied Disorders. A Contribution to the Pathology of Nerve-Storms. London, Arts & Boeve Nijmegen, 1873.
10. Gowers WR: A Manual of Diseases of the Nervous System. Philadelphia, Blakiston, 1888.
11. Graham JR, Wolff HG: Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry 1938;39:737-763.
12. Tunis MM, Wolff HG: Long-term observations of the reactivity of the cranial arteries in subjects with vascular headache of the migraine type. Arch Neurol Psychiatry 1953;70:551-557.
13. Limmroth V, May A, Auerbach P, Wosnitza G, Eppe T, Diener HC: Changes in cerebral blood flow velocity after treatment with sumatriptan or placebo and implications for the pathophysiology of migraine. J Neurol Sci 1996;138:60-65.
14. Kruuse C, Thomsen LL, Birk S, Olesen J: Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 2003;126:241-247.
15. Chapman LF, Ramos AO, Goodell H, Silverman G, Wolff HG: A humoral agent implicated in vascular headache of the migraine type. Arch Neurol 1960;3:223-229.
16. Goadsby PJ, Edvinsson L, Ekman R: Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990;28:183-187.
17. Moskowitz MA, Cutrer FM: Sumatriptan: a receptor-targeted treatment for migraine. Annu Rev Med 1993;44:145-154.
18. Sarchielli P, Alberti A, Codini M, Floridi A, Gallai V: Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia 2000;20:907-918.
19. May A, Shepheard SL, Knorr M, et al: Retinal plasma extravasation in animals but not in humans: implications for the pathophysiology of migraine. Brain 1998;121:1231-1237.
20. Goadsby PJ, Zagami AS, Lambert GA: Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache 1991;31:365-371.
21. May A, Goadsby PJ: Substance P receptor antagonists in the therapy of migraine. Expert Opin Investig Drugs 2001;10:673-678.
22. Afridi SK, Matharu MS, Lee L, et al: A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain 2005;128:932-939.
23. Strassman AM, Raymond SA, Burstein R: Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996;384:560-564.
24. Parsons AA: Recent advances in mechanisms of spreading depression. Curr Opin Neurol 1998;11:227-231.
25. Olesen J, Larsen B, Lauritzen M: Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol 1981;9:344-352.
26. Lashley KS: Patterns of cerebral integration indicated by the scotomas of migraine. Arch Neurol Psychiatry 1942;46:331-339.
27. Leao A: Spreading depression of activity in the cerebral cortex. J Neurophysiol 1944;7:359-390.
28. Lauritzen M: Pathophysiology of the migraine aura. The spreading depression theory. Brain 1994;117:199-210.
29. Hadjikhani N, Sanchez del Rio M, Wu O, et al: Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA 2001;98:4687-4692.
30. Sanchez del Rio M, Bakker D, Wu O, et al: Perfusion weighted imaging during migraine: spontaneous visual aura and headache. Cephalalgia 1999;19:701-707.
31. Bowyer SM, Aurora KS, Moran JE, Tepley N, Welch KM: Magnetoencephalographic fields from patients with spontaneous and induced migraine aura. Ann Neurol 2001;50:582-587.
32. Spierings EL: Recent advances in the understanding of migraine. Headache 1988;28:655-658.
33. Terwindt GM, Ferrari MD, Tijhuis M, Groenen SMA, Picavet HSJ, Launer LJ: The impact of migraine on quality of life in the general population: the GEM study. Neurology 2000;55:624-629.
34. Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF: Migraine, quality of life, and depression: a population-based case-control study. Neurology 2000;55:629-635.
35. Breslau N, Davis GC: Migraine, physical health and psychiatric disorder: a prospective epidemiologic study in young adults. J Psychiatr Res 1993;27:211-221.
36. Ottman R, Lipton RB: Comorbidity of migraine and epilepsy. Neurology 1994;44:2105-2110.
37. Miller D, Waters DD, Warnica W, Szlachcic J, Kreeft J, Theroux P: Is variant angina the coronary manifestation of a generalized vasospastic disorder? N Engl J Med 1981;304:763-766.
38. Lafitte C, Even C, Henry-Lebras F, Toffol B, Autret A: Migraine and angina pectoris by coronary artery spasm. Headache 1996;36:332-334.
39. Gamberini G, D'Alessandro R, Labriola E, Poggi V, Manzoni GC, Carpeggiana P, Sacquegna T: Further evidence on the association of mitral valve prolapse and migraine. Headache 1984;24:39-40.
40. Milhaud D, Bogousslavsky J, van Melle G, Liot P: Ischemic stroke and active migraine. Neurology 2001;57:1805-1811.
41. Carolei A, Marini C, De Matteis C: History of migraine and risk of cerebral ischaemia in young adults. The Italian National Research Council Study Group on Stroke in the Young. Lancet 1996;347:1503-1506.
42. Schwaag S, Nabavi DG, Frese A, Husstedt IW, Evers S: The association between migraine and juvenile stroke: a case-control study. Headache 2003;43:90-95.
43. Tzourio C, Tehindrazanarivelo A, Iglesias S, et al: Case-control study of migraine and risk of ischaemic stroke in young women. BMJ 1995;310:830-833.
44. Kruit MC, van Buchem MA, Hofman PA, et al: Migraine as a risk factor for subclinical brain lesions. JAMA 2004;291:427-434.
45. Rocca MA, Colombo B, Inglese M, Codella M, Comi G, Filippi M: A diffusion tensor magnetic resonance imaging study of brain tissue from patients with migraine. J Neurol Neurosurg Psychiatry 2003;74:501-503.
46. Moorman A, Webb S, Brown NA, Lamers W, Anderson RH: Development of the heart. 1. Formation of the cardiac chambers and arterial trunks. Heart 2003;89:806-814.
47. Anderson RH, Webb S, Brown NA, Lamers W, Moorman A: Development of the heart. 2. Septation of the atriums and ventricles. Heart 2003;89:949-958.
48. Kiserud T: Fetal venous circulation - An update on hemodynamics. J Perinat Med 2000;28:90-96.
49. Rasanen J, Wood DC, Weiner S, Ludomirski A, Huhta JC: Role of the pulmonary circulation in the distribution of human fetal cardiac output during the second half of pregnancy. Circulation 1996;94:1068-1073.
50. Kerut EK, Norfleet WT, Plotnick GD, Giles TD: Patent foramen ovale: a review of associated conditions and the impact of physiological size. J Am Coll Cardiol 2001;38:613-623.
51. Thompson T, Evans W: Paradoxical embolism. Q J Med 1930;23:135-152.
52. Hagen PT, Scholz DG, Edwards WD: Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 1984;59:17-20.
53. Fisher DC, Fisher EA, Budd JH, Rosen SE, Goldman ME: The incidence of patent foramen ovale in 1,000 consecutive patients. A contrast transesophageal echocardiography study. Chest 1995;107:1504-1509.
54. Meissner I, Whisnant JP, Khandheria BK, et al: Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Stroke Prevention: Assessment of Risk in a Community. Mayo Clin Proc 1999;74:862-869.
55. Lechat P, Mas JL, Lascault G, Loron P, Theard M, Klimczac M, Dorobinski G, Thomas D, Grosgogeat Y: Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988;318:1148-1152.
56. Overell JR, Bone I, Lees KR: Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology 2000;55:1172-1179.
57. Di TM, Sacco RL, Gopal A, Mohr JP, Homma S: Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med 1992;117:461-465.
58. Mas JL, Arquizan C, Lamy C, et al: Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001;345:1740-1746.
59. Moon RE, Camporesi EM, Kisslo JA: Patent foramen ovale and decompression sickness in divers. Lancet 1989;i:513-514.
60. Wilmshurst PT, Byrne JC, Webb-Peploe MM: Relation between interatrial shunts and decompression sickness in divers. Lancet 1989;ii:1302-1306.
61. Dear WE, Chen P, Barasch E, Anderson HV, Varughese AT, Macris MP: Sixty-eight-year-old woman with intermittent hypoxemia. Circulation 1995;91:2284-2289.
62. Kawamata T, Takeshita M, Ishizuka N, Hori T: Patent foramen ovale as a possible risk factor for cryptogenic brain abscess: report of two cases. Neurosurgery 2001;49:204-206.
63. Klotzsch C, Sliwka U, Berlit P, Noth J: An increased frequency of patent foramen ovale in patients with transient global amnesia. Analysis of 53 consecutive patients. Arch Neurol 1996;53:504-508.
64. Mori S, Sadoshima S, Tagawa K, Iino K, Fujishima M: Massive spinal cord infarction with multiple paradoxical embolism: a case report. Angiology 1993;44:251-256.
65. Chaikof EL, Campbell BE, Smith RB 3rd: Paradoxical embolism and acute arterial occlusion: rare or unsuspected? J Vasc Surg 1994;20:377-384.
66. Carey HB, Boltax R, Dickey KW, Finkelstein FO: Bilateral renal infarction secondary to paradoxical embolism. Am J Kidney Dis 1999;34:752-755.
67. Agostoni P, Gasparini G, Destro G: Acute myocardial infarction probably caused by paradoxical embolus in a pregnant woman. Heart 2004;90:12e.
68. Koullias GJ, Elefteriades JA, Wu I, Jovin I, Jadbabaie F, McNamara R: Massive paradoxical embolism: caught in the act. Circulation 2004;109:3056-3057.
69. Lamy C, Giannesini C, Zuber M, et al: Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA study. Atrial Septal Aneurysm. Stroke 2002;33:706-711.
70. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP: Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 2002;105:2625-2631.
71. Devuyst G, Despland PA, Bogousslavsky J, Jeanrenaud X: Complementarity of contrast transcranial Doppler and contrast transesophageal echocardiography for the detection of patent foramen ovale in stroke patients. Eur Neurol 1997;38:21-25.
72. Job FP, Ringelstein EB, Grafen Y, et al: Comparison of transcranial contrast Doppler sonography and transesophageal contrast echocardiography for the detection of patent foramen ovale in young stroke patients. Am J Cardiol 1994;74:381-384.
73. Steiner MM, Di Tullio MR, Rundek T, et al: Patent foramen ovale size and embolic brain imaging findings among patients with ischemic stroke. Stroke 1998;29:944-948.
74. Stone DA, Godard J, Corretti MC, et al: Patent foramen ovale: association between the degree of shunt by contrast transesophageal echocardiography and the risk of future ischemic neurologic events. Am Heart J 1996;131:158-161.
75. Schuchlenz HW, Weihs W, Horner S, Quehenberger F: The association between the diameter of a patent foramen ovale and the risk of embolic cerebrovascular events. Am J Med 2000;109:456-462.
76. Knauth M, Ries S, Pohimann S, et al: Cohort study of multiple brain lesions in sport divers: role of a patent foramen ovale. BMJ 1997;314:701-705.
77. Germonpre P, Dendale P, Unger P, Balestra C: Patent foramen ovale and decompression sickness in sports divers. J Appl Physiol 1998;84:1622-1626.
78. Devuyst G, Bogousslavsky J, Ruchat P, et al: Prognosis after stroke followed by surgical closure of patent foramen ovale: a prospective follow-up study with brain MRI and simultaneous transesophageal and transcranial Doppler ultrasound. Neurology 1996;47:1162-1166.
79. Martin F, Sanchez PL, Doherty E, et al: Percutaneous transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Circulation 2002;106:1121-1126.
80. Walsh KP, Wilmshurst PT, Morrison WL: Transcatheter closure of patent foramen ovale using the Amplatzer septal occluder to prevent recurrence of neurological decompression illness in divers. Heart 1999;81:257-261.
81. Bogousslavsky J, Garazi S, Jeanrenaud X, Aebischer N, van Melle G: Stroke recurrence in patients with patent foramen ovale: the Lausanne Study. Lausanne Stroke with Paradoxal Embolism Study Group. Neurology 1996;46:1301-1305.
82. Sztajzel R, Genoud D, Roth S, Mermillod B, Le Floch-Rohr J: Patent foramen ovale, a possible cause of symptomatic migraine: a study of 74 patients with acute ischemic stroke. Cerebrovasc Dis 2002;13:102-106.
83. Anzola GP, Magoni M, Guindani M, Rozzini L, Dalla VG: Potential source of cerebral embolism in migraine with aura: a transcranial Doppler study. Neurology 1999;52:1622-1625.
84. Del Sette M, Angeli S, Leandri M, et al: Migraine with aura and right-to-left shunt on transcranial Doppler: a case-control study. Cerebrovasc Dis 1998;8:327-330.
85. Domitrz I, Mieszkowski J, Kwiecinski H: The prevalence of patent foramen ovale in patients with migraine. Neurol Neurochir Pol 2004;38:89-92.
86. Carerj S, Narbone MC, Zito C, et al: Prevalence of atrial septal aneurysm in patients with migraine: an echocardiographic study. Headache 2003;43:725-728.
87. Kurth T, Slomke MA, Kase CS, et al: Migraine, headache, and the risk of stroke in women: a prospective study. Neurology 2005;64:1020-1026.
88. Tsimikas S: Transcatheter closure of patent foramen ovale for migraine prophylaxis: hope or hype? J Am Coll Cardiol 2005;45:496-498.
89. Buring JE, Peto R, Hennekens CH: Low-dose aspirin for migraine prophylaxis. JAMA 1990;264:1711-1713.
90. Bensenor IM, Cook NR, Lee IM, Chown MJ, Hennekens CH, Buring JE: Low-dose aspirin for migraine prophylaxis in women. Cephalalgia 2001;21:175-183.
91. Rodes-Cabau J, Molina C, Serrano-Munuera C, et al: Migraine with aura related to the percutaneous closure of an atrial septal defect. Catheter Cardiovasc Interv 2003;60:540-542.
92. Yankovsky AE, Kuritzky A: Transformation into daily migraine with aura following transcutaneous atrial septal defect closure. Headache 2003;43:496-498.
93. Meyer JS, Terayama Y, Konno S, et al: Age-related cerebrovascular disease alters the symptomatic course of migraine. Cephalalgia 1998;18:202-208.
94. Mortelmans K, Post M, Thijs V, Herroelen L, Budts W: The influence of percutaneous atrial septal defect closure on the occurrence of migraine. Eur Heart J 2005;26:1533-1537.
95. Venketasubramanian N, Sacco RL, Di Tullio M, Sherman D, Homma S, Mohr JP: Vascular distribution of paradoxical emboli by transcranial Doppler. Neurology 1993;43:1533-1535.
96. Hayashida K, Fukuchi K, Inubushi M, Fukushima K, Imakita S, Kimura K: Embolic distribution through patent foramen ovale demonstrated by (99m)Tc-MAA brain SPECT after Valsalva radionuclide venography. J Nucl Med 2001;42:859-863.
97. Couch JR, Hassanein RS: Platelet aggregability in migraine. Neurology 1977;27:843-848.
98. Zeller JA, Frahm K, Baron R, Stingele R, Deuschl G: Platelet-leukocyte interaction and platelet activation in migraine: a link to ischemic stroke? J Neurol Neurosurg Psychiatry 2004;75:984-987.
99. Fragoso YD: Reduction of migraine attacks during the use of warfarin. Headache 1997;37:667-668.
100. Wammes-van der Heijden EA, Tijssen CC, van't Hoff AR, Egberts AC: A thromboembolic predisposition and the effect of anticoagulants on migraine. Headache 2004;44:399-402.
101. Robbins L: Migraine and anticardiolipin antibodies - Case reports of 13 patients, and the prevalence of antiphospholipid antibodies in migraineurs. Headache 1991;31:537-539.
102. Hughes GR: Migraine, memory loss, and 'multiple sclerosis'. Neurological features of the antiphospholipid (Hughes') syndrome. Postgrad Med J 2003;79:81-83.
103. D'Amico D, Moschiano F, Leone M, et al: Genetic abnormalities of the protein C system: shared risk factors in young adults with migraine with aura and with ischemic stroke? Cephalalgia 1998;18:618-621.
104. D'Amico D, Moschiano F, Attanasio A, Erba N, Ciusani E, Schieroni F, Bussone G: Hyperhomocysteinemia in patients with migraine with aura. Cephalalgia 2003;23:742.
105. Kowa H, Yasui K, Takeshima T, Urakami K, Sakai F, Nakashima K: The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. Am J Med Genet 2000;96:762-764.
106. Kara I, Sazci A, Ergul E, Kaya G, Kilic G: Association of the C677T and A1298C polymorphisms in the 5,10 methylenetetrahydrofolate reductase gene in patients with migraine risk. Brain Res Mol Brain Res 2003;111:84-90.
107. Hering-Hanit R, Friedman Z, Schlesinger I, Ellis M: Evidence for activation of the coagulation system in migraine with aura. Cephalalgia 2001;21:137-139.
108. Moschiano F, D'Amico D, Ciusani E, et al: Coagulation abnormalities in migraine and ischaemic cerebrovascular disease: a link between migraine and ischaemic stroke? Neurol Sci. 2004;25(suppl 3):S126-S128.
109. Angeli S, Carrera P, Del SM, et al: Very high prevalence of right-to-left shunt on transcranial Doppler in an Italian family with cerebral autosomal dominant angiopathy with subcortical infarcts and leukoencephalopathy. Eur Neurol 2001;46:198-201.
110. Ali MM, Farooqui FA, Sohal GS: Ventrally emigrating neural tube cells contribute to the normal development of heart and great vessels. Vascul Pharmacol 2003;40:133-140.
111. Sohal GS, Ali MM, Ali AA, Dai D: Ventrally emigrating neural tube cells contribute to the formation of Meckel's and quadrate cartilage. Dev Dyn 1999;216:37-44.
112. Baker CV, Bronner-Fraser M: Vertebrate cranial placodes. 1. Embryonic induction. Dev Biol 2001;232:1-61.
113. Karttunen V, Ventila M, Ikaheimo M, Niemela M, Hillbom M: Ear oximetry: a noninvasive method for detection of patent foramen ovale: a study comparing dye dilution method and oximetry with contrast transesophageal echocardiography. Stroke 2001;32:448-453.
114. Devuyst G, Piechowski-Jozwiak B, Karapanayiotides T, et al: Controlled contrast transcranial Doppler and arterial blood gas analysis to quantify shunt through patent foramen ovale. Stroke 2004;35:859-863.
115. Pitt BR, Hammond GL, Gillis CN: Comparison of pulmonary and extrapulmonary extraction of biogenic amines. J Appl Physiol 1982;52:1545-1551.
116. Gimmel'farb GN, Guliamov DS, Karimova TZ, Gerasimov NM: Vasoactive hormone metabolism in the lungs of patients with congenital heart defects. Kardiologiia 1987;27:61-65.
117. Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL: Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons. Lancet 2000;356:1648-1651.
118. Onorato E, Melzi G, Casilli F, et al: Patent foramen ovale with paradoxical embolism: mid-term results of transcatheter closure in 256 patients. J Interv Cardiol 2003;16:43-50.
119. Morandi E, Anzola GP, Angeli S, Melzi G, Onorato E: Transcatheter closure of patent foramen ovale: a new migraine treatment? J Interv Cardiol 2003;16:39-42.
120. Post MC, Thijs V, Herroelen L, Budts WI: Closure of a patent foramen ovale is associated with a decrease in prevalence of migraine. Neurology 2004;62:1439-1440.
121. Schwerzmann M, Wiher S, Nedeltchev K, et al: Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks. Neurology 2004;62:1399-1401.
122. Azarbal B, Tobis J, Suh W, Chan V, Dao C, Gaster R: Association of interatrial shunts and migraine headaches: impact of transcatheter closure. J Am Coll Cardiol 2005;45:489-492.
123. Reisman M, Christofferson RD, Jesurum J, et al: Migraine headache relief after transcatheter closure of patent foramen ovale. J Am Coll Cardiol 2005;45:493-495.